Can you ship peptides internationally?

Can you ship peptides to Canada?

A U.S. shipper can send a peptide to Canada only if the specific item meets both U.S. export rules and Canadian import rules. The U.S. Postal Service says drugs and medicines mailed to Canada must comply with Canadian law, and Health Canada treats shipments imported for sale as commercial imports that must meet its requirements. Confirm each before you buy a label. [6][9][10]

Health Canada says shipments imported for the purpose of sale in Canada are considered commercial imports and must meet the applicable regulatory requirements. [9] The Canada Border Services Agency says the country of origin is where goods are made, produced or grown, and it may not always be the same as the country they are shipped from. [14] The Automated Export System is the system for collecting, processing, and storing Electronic Export Information from persons or entities exporting goods from the United States. [4]

A label or a carrier booking does not answer every border question. Keep the U.S. export decision, the postal service decision, and the Canadian product and importer decisions in separate records. That separation lets you find the missing evidence before a parcel reaches customs. [2] [5] [10]

This guide follows a U.S. shipper sending an identified item to a Canadian consignee. Australia and New Zealand illustrate different destination rules. Each later shipment needs its own item, consignee, destination, and service review. [6] [7] [8] [16] [20]

Key Facts

• USPS says drugs and medicines mailed to Canada must comply with Canadian law. [6]
• BIS says that EAR99 items do not require a license for export in most situations, but may require one if destined for a prohibited or restricted end user, end use or destination of concern. [3]
• Health Canada says importers are responsible for ensuring health products imported for sale comply with the Act and its Regulations at the time of import. [10]
• Health Canada says an importer must have an Establishment Licence for the activity of import for the category of API, and human drugs must have a Drug Identification Number before being marketed in Canada. [11][12]
• Health Canada says products found non compliant during inspection will be refused entry or seized, and CBSA officers may detain a health product they suspect does not comply. [25][26]
• The Australian TGA says peptide products regulated as therapeutic goods must be included in the ARTG before they can be imported, manufactured, supplied, exported or advertised, and that disclaimers such as research use only or not for human use do not change whether a product is regulated as a therapeutic good. [16][18]
• USPS says a false, misleading or incomplete customs declaration can result in seizure or return of the item and criminal or civil penalties. [24]
• Medsafe says the categorisation of a product is determined by its ingredients, its purpose for use and the manner in which it is presented in the market. [20]

TL;DR

Identify the item and its actual transaction first. Have the U.S. export questions, USPS country conditions, and Canadian importer requirements answered by the responsible people before a label is purchased. A complete invoice and declaration describe the same real goods; neither substitutes for Canadian authorization. [2] [6] [10] [22] [23]

Cross border scope and product identity

Define the exact item and transaction before asking whether it may cross the Canadian border. A name such as “peptide” does not resolve which product category, import condition, or export classification applies. The country receiving the goods makes its own destination decision, while the U.S. shipper still has a separate export inquiry. [2] [10]

Build an origin and destination record with two columns. In the U.S. column, enter the item identifier used in your inventory, manufacturer, composition evidence, actual intended purpose, seller, exporter, and evidence used for export classification. In the Canada column, enter the named buyer, consignee, importer, proposed product category, contemplated use, and the Canadian authority or qualified reviewer who will confirm that category. These fields are a worksheet for obtaining a determination, not a category decision by themselves. [1] [2] [10]

Keep the item's stated purpose beside its surrounding evidence. Under the U.S. intended use rule, intent may be shown by expressions, design or composition, and distribution circumstances. A research label is one part of that record, not a standalone conclusion. 1] For the broader meaning of research language, use [Research use only: what it actually means. For the general mailing and item intake decision, read Can you mail peptides?; this article applies those facts to U.S. export and destination import gates. The mailing decision record covers general shipment records and hold points; this article adds the foreign importer, destination authority, and border response fields.

Suppose, hypothetically, your order record describes one unidentified laboratory material, while the invoice describes only “sample.” Neither term establishes what Canada will classify. Ask the Canadian importer to reconcile the physical item, supporting composition record, claimed purpose, buyer role, and invoice description before tender. If the buyer identifies a regulated category, use that category's applicable import path. If classification remains unresolved, keep the order on hold and ask Health Canada or qualified Canadian counsel the precise classification question. [10]

Treat each transaction field as a possible source of mismatch. A consignee may differ from a buyer; the manufacturer may differ from the U.S. dispatch address; and the person who arranges transport may differ from the importer. The worksheet should name each role rather than leave the carrier to infer it. The point is to give the reviewer the actual facts needed to apply the cited rules. [10] [14] [23]

The U.S. export control and filing gate

Resolve export classification and the Electronic Export Information question separately before the U.S. shipment leaves. BIS describes ECCN classification as a step after confirming that an item is subject to the Export Administration Regulations, or EAR. Census describes the Automated Export System, or AES, as the system collecting Electronic Export Information, or EEI, from exporters of goods from the United States. These are different questions. [2] [4]

Start the export control worksheet with the actual item record. Give the reviewer its composition, manufacturer information, technical description, intended recipient, stated end use, and destination. Ask first whether that item is subject to the EAR. If it is, ask for the Export Control Classification Number, or ECCN, or a documented EAR99 determination. Then ask whether the classification and this transaction call for a licence. Do not assign a code to an unnamed peptide by analogy with another product. BIS presents classification as part of deciding whether a licence is required for the actual export transaction. [2]

An EAR99 result is not a general release stamp. BIS says EAR99 items generally do not require a licence, but may require one because of a restricted end user, end use, or destination of concern. Record the parties and the purpose that the reviewer actually assessed. A new consignee or changed use calls for a fresh transaction question even when the inventory item is unchanged. [3]

Keep a separate EEI line in the same file. Name the person or entity responsible for resolving whether EEI must be transmitted through AES for this transaction. Census identifies AES as the collection and processing system; that description alone does not determine a filing threshold or exemption for your parcel. Ask the responsible export reviewer for the applicable filing rule, any documentation supporting a no filing conclusion, and the submission reference if a filing is made. [4]

Use a short decision tree rather than an assumed clearance:

1. Is the exact item subject to the EAR? Record the basis and reviewer. [2]

2. If it is, what is its ECCN or supported EAR99 determination? Record the product facts used. [2]

3. Does the classification together with the recipient, end use, and destination require a licence? Record the answer for this transaction. [2] [3]

4. Who resolves the separate EEI filing question, and what filing or documented conclusion results? Record the responsible party. [4]

5. Has the Canadian importer reached its own admissibility conclusion? Put that result in the Canadian record; the U.S. answers do not decide it. [10]

This sequence helps you direct questions to the right reviewer. It does not supply an ECCN, licence decision, or EEI exemption. If the available item description cannot support classification, improve the product record before trying to infer an answer from a carrier form. Keep export documents linked to the version of the order they describe so a changed buyer or destination can be reviewed without confusing an earlier determination with the current parcel. [2] [3] [4]

The U.S. export file and the carrier file should agree on item identity. A postal declaration that calls the item by a different generic description can defeat the value of a careful export review. Compare the reviewer’s item identifier, invoice goods description, consignee, and destination before release. That is a practical consistency check, not a substitute for the reviewer’s export conclusion. [2] [22] [23]

USPS country conditions and service eligibility

Check the current USPS international conditions and the individual destination listing for the identified item and service. USPS Publication 52 directs international mailers to individual country listings for additional mailing conditions. Those listings can impose different restrictions for the same broad product family. [5]

Read a country listing as a condition for that postal route, not a full import permit. Canada’s listing points to Canadian law; it does not itself settle the product's category. Australia's listing names a permit condition, while the TGA has a separate therapeutic goods analysis. New Zealand presents an even sharper postal question: when the item is a medicine, USPS lists that class under prohibitions. An unclassified material needs a classification decision before you apply that word to it. [6] [7] [8] [16] [20]

Write down the destination, selected USPS service, item description, listing entry, applicable condition, and the date you checked it. Ask USPS for a service specific answer if the listing and the actual item leave an acceptance question unresolved. A booking screen or postage price answers a different operational question. The sender remains responsible for bringing the real item and destination facts to the carrier and relevant authority. [5] [6] [7] [8]

After route and item eligibility are resolved, use the peptide shipping packaging specification for packout design. Packaging can protect an item in transit, but it cannot establish whether the chosen international service or destination accepts that item. Keep the USPS country listing and service response with the destination determination so fulfillment can match the reviewed item and route. [5]

Canada’s commercial importer and product gate

The Canadian importer must establish the actual product category and applicable authorization before a shipment imported for sale reaches Canada. Health Canada classifies shipments imported for sale in Canada as commercial imports and says importers must ensure compliance at import, including Canadian market authorization where applicable and appropriately licensed importers. [9] [10]

Use a category matrix for the Canadian question. It prevents a seller's U.S. product label from silently becoming a Canadian regulatory answer.

Do not choose the most convenient matrix row based on marketing vocabulary. A U.S. research purpose, a manufacturer's catalog category, and a buyer's informal description can differ. Give the Canadian reviewer the composition, presentation, intended recipient, proposed use, and commercial arrangement. Under the U.S. intended use rule, expressions and distribution circumstances matter to the U.S. inquiry; the Canadian importer must separately resolve the Canadian classification. [1] [10]

Health Canada's commercial guidance distinguishes categories and conditions. For the API row, its table expressly names an Establishment Licence for API import activity. For human drugs marketed in Canada, it expressly names a Drug Identification Number. Neither quoted condition establishes that every item called a peptide is an API or a human drug. If your identified item raises another category or activity question, put that question to Health Canada rather than transporting a conclusion from one row to another. [10] [11] [12]

Ask who is the Canadian importer of record in the actual transaction. The U.S. seller may sell to a Canadian business, send to a consignee, or participate in a more complicated fulfillment arrangement. The role names in the contract and invoice must match the party whose authorizations are being relied on. Health Canada places responsibility on importers to ensure health products imported for sale comply at the time of import. [10] The invoice separately identifies seller, receiver, and consignee where they differ. [23]

If someone proposes a personal import rationale for stock intended for resale, return to the transaction purpose. Health Canada says shipments imported for sale are commercial imports. [9] Ask the Canadian importer to document the commercial path that applies. Do not copy rules for an individual's own use into a sale to a business, and do not describe research labeling as an exemption. The question is the identified product, intended transaction, and applicable authority, not a phrase on the carton. [1] [9] [10]

Maintain a dated importer determination record. Include the person who evaluated the category, the source or agency response they used, the product version, the importer name, and any authorization reference. Health Canada's GUI-0117 commercial guidance is dated December 2020; ask the importer to confirm the current rule and licence status for the contemplated shipment. 10] If the item, consignee, or sale purpose changes, reopen the corresponding question instead of extending an earlier answer beyond its facts. See also [Peptide Product Recall and Mock-Recall Drill: A Bounded Operator Workflow.

The decision is ready for the customs packet only after the importer can tie a specific product and activity to the relevant authorization record, or can explain why a different documented rule applies. If that evidence is pending, the correct operational state is a hold. A fulfillment handoff should state the missing question in plain terms, such as “Canadian importer to confirm product category and import activity,” so a packer does not treat a blank field as permission. [10] [13]

Canada’s customs release packet

Assemble the Canadian importer's product, origin, customs, and contact evidence before the commercial parcel reaches CBSA. Health Canada says importers should reference or include applicable product licence numbers, establishment licence numbers, or other import documents so CBSA and Health Canada can make a timely admissibility decision. CBSA also requires the importer to establish origin and tariff treatment for commercial goods. [13] [14] [28]

Use a handoff packet with named owners rather than a folder of unlabeled files:

Origin deserves its own review. CBSA says country of origin is where goods are made, produced, or grown and may differ from the country they ship from. A U.S. dispatch address therefore cannot be copied into the manufacturing origin field without checking the manufacturing record. [14] If the manufacturer is elsewhere, ask the importer or broker how to document that actual origin. CBSA says the Canadian tariff classification number and country of origin are used to find tariff treatment. [28]

Confirm the party handling the Canadian import account. CBSA says nonresident importers must contact the Canada Revenue Agency for a business number before registering in CARM. [15] That condition applies to the nonresident importer described by CBSA, not automatically to every U.S. seller. Ask the named importer and broker which business and release records this arrangement requires. Do not assign an import account responsibility merely because one party pays postage.

The packet should travel with a clear index. Put the product identifier and shipment reference on each authorization copy or reference line; state which importer and activity the evidence covers; and give the broker a contact who can retrieve originals if requested. Health Canada specifically recommends references or copies in the shipment for applicable authorizations. [13] The goal is to connect a regulator's question to the correct product and licensed party quickly, not to bury a missing authorization under extra documents.

CBSA says release of commercial goods depends on meeting requirements that include a commercial accounting declaration and payment of duties and taxes within required timeframes. [29] The importer or broker should name who prepares that declaration and handles the resulting amounts. The U.S. shipper's postal customs form remains a separate document; a completed U.S. form does not answer who will account for the goods in Canada. Reconcile the two records on item, origin, parties, and value before shipment. [23] [29]

If you use a fulfillment partner, assign the evidence owner before handing over the parcel. The partner may print the approved invoice and declaration from agreed fields, while the importer and its reviewers provide the Canadian regulatory and customs decisions. For a broader fulfillment role discussion, see How to choose a peptide 3PL. This packet owns the Canada release evidence for the particular order. [10] [13] [23]

Australia’s therapeutic goods gate

For an Australian destination, determine whether the identified peptide is a therapeutic good and whether the required destination authority and postal conditions are met. TGA says peptide products regulated as therapeutic goods must be included in the Australian Register of Therapeutic Goods, or ARTG, before import, unless a limited specific approval, authority, or exemption applies. [16] [17]

Start with the proposed product, presentation, consignee, and transaction. Ask the Australian reviewer or TGA whether the actual item is regulated as a therapeutic good. If it is, request the ARTG entry or the specific approval, authority, or exemption being relied on. Record its holder, product scope, and activity. Do not infer from a different product's ARTG status that the item in your parcel is covered. [16] [17]

The TGA statement covers import, manufacture, supply, export, and advertising when a peptide product is regulated as a therapeutic good. [16] Ask the Australian reviewer to name the activity that this shipment enables, the party performing it, and the authorization that applies to that activity. A register entry and a specific exception are different evidence: record which one supports the proposed activity, along with the matching product identity. [16] [17]

For the postal condition, use the USPS country conditions and service eligibility section's Australia entry and record its item specific outcome beside the TGA determination. [7]

The decision tree is concise:

1. What is the identified product and how will it be presented and supplied? Give those facts to the Australian reviewer. [16] [18]

2. Does TGA regulate that product as a therapeutic good? If yes, ask for its ARTG entry or a specific applicable approval, authority, or exemption. [16] [17]

3. Does the intended transaction rely on a personal import scheme? If this is commercial supply, TGA says its personal import scheme does not allow commercial supply of unapproved therapeutic goods. [19]

4. Are the authorization holder, consignee, item description, and shipment documents aligned? Resolve inconsistencies before release. [16]

An RUO phrase cannot settle the TGA question. TGA explicitly says disclaimers that a product is for research use only or not for human use do not change whether it is regulated as a therapeutic good. [18] Treat the label as an item fact to disclose, not a route around classification. The same page's personal import discussion must stay separate from a commercial shipment to an Australian buyer. [19]

A U.S. export finding does not establish Australian therapeutic goods eligibility. Keep a dated product classification answer and the applicable ARTG or exception reference with the Australian order. An Australian reviewer should match the holder, identified product, and proposed import activity to that reference before the shipper relies on it. [2] [16] [17]

If the Australian authority identifies a condition that the proposed importer cannot meet, suspend that transaction. Ask the authority or qualified Australian counsel what evidence would resolve the actual product and activity, and preserve the answer with the order record. No research label or generic invoice wording substitutes for that determination. [16] [18]

New Zealand’s postal and medicine import gates

For New Zealand, use the USPS country conditions and service eligibility section for the postal decision, then resolve the separate medicine category and commercial import questions with New Zealand authorities. [8] [20] [21]

Build the New Zealand category request around three separate inputs: an ingredient identification record, the purpose communicated to the buyer, and the proposed listing or package presentation. Medsafe names all three as categorization factors. [20] Ask the local reviewer to state which inputs it considered and the category reached for this identified version. Preserve the response with the product record so the importer and shipper use the same answer when assembling authority and invoice materials. [20]

The commercial import rule also has its own subject. New Zealand Customs describes importing medicines for commercial purposes as importing them for other than the importing person's personal use. It says such import requires a Ministry of Health licence allowing sale, supply, or distribution of medicines of that nature, or the specified entitlement to a licensing exemption together with ministerial consent. [21] A buyer's assertion that it will research an item does not itself prove either branch. Ask the importer for the documented basis that applies to its actual activity. If the importer relies on a Ministry of Health licence, record the licence holder, the nature of medicines it covers, and whether it authorizes the proposed sale, supply, or distribution. If it relies on an exemption, record the stated exemption basis and the ministerial consent. Send mismatches to the named New Zealand authority or qualified local reviewer before committing the order. [21]

Retain the classification response with the inventory item and shipment version. If the product's composition, label, presentation, buyer, or purpose changes, ask whether the previous answer still applies. Medsafe's stated categorization factors make those changes relevant to review. [20] A process that copies a Canada clearance or an Australia ARTG reference into a New Zealand order cannot answer the New Zealand questions. [10] [16] [20]

For a commercial medicine transaction, have the importer establish the exact New Zealand Customs licence or exemption and consent basis. Record which branch the importer relies on and who holds each document. Hold the transaction for authority review if the basis remains unresolved. [21]

The international declaration and invoice

Describe the actual goods truthfully and consistently on the USPS customs declaration and any required commercial invoice. USPS calls for a detailed contents description, with quantity, net weight, and value for each declared item. Its invoice instructions specify seller, receiver, consignee where different, origin, destination, reason for export, value, terms, currency, and merchandise details where an invoice is required. [22] [23]

Use the Can you mail peptides? worksheet for general item description and quantity checks. Use these remaining fields to reconcile the international invoice with the Canada release record before generating a label:

Do a discrepancy pass with the person responsible for the product record and the person preparing the export documents. Compare manufacturing origin, buyer, consignee, destination, declared value, and any applicable authorization reference. A field should prompt a correction or a question when it disagrees with the supporting record. Do not solve uncertainty with a broad label such as “research sample” if that label fails to identify the real merchandise. USPS warns that a false, misleading, or incomplete declaration can result in seizure, return, or criminal or civil penalties. [22] [23] [24]

The invoice may carry more information than the postal declaration. USPS says a commercial invoice must be completed where required and lists basic fields that include seller and receiver contact information, a separate consignee when relevant, origin, destination, reason for export, commercial value, terms, currency, quantities, description, and a correctness statement. [23] Assign one person to verify that the two documents describe the same transaction. A broker may need additional destination information, which the named importer should identify for the actual shipment. [13] [23]

Avoid assigning a tariff code by guessing from a broad item name. CBSA says a Canadian tariff classification number together with country of origin determines tariff treatment. [28] Have the importer or broker document the classification used for Canada, and compare its goods description with the invoice. The U.S. export classification and the Canadian tariff classification serve different decisions. [2] [28]

Detention, refusal, and release evidence

If a border authority holds the shipment, preserve the notice and route its stated question to the named importer or qualified counsel before another tender. Health Canada's commercial guidance says CBSA officers may detain health products they suspect do not comply, and Health Canada can refuse entry or seize products found noncompliant during inspection. [25] [26]

Use the notice as the starting point. Record the shipment identifier, item and batch identity, importing party, agency issuing the notice, date, and exact defect or request stated. Ask the importer to compare it with the product authorization, importer licence, invoice, origin evidence, and customs account record. The goal is to answer the issue the authority actually raised. Do not send a generic explanation that ignores the cited field or product. [13] [25] [27]

Health Canada says it will notify affected parties and CBSA in writing when it deems a product inadmissible, including seizure notice and disposition options where applicable. [27] Give that written decision to the Canadian importer and counsel. They can determine what response, document, correction, or disposition is available for that case. The shipper should retain the correspondence and stop repeat shipments of the same unresolved item and arrangement while the defect is assessed. A promise of release would go beyond the cited guidance. [26] [27]

Separate a customs hold from physical loss. A parcel that cannot be located raises a different operational problem; the shipping damage and loss guide addresses that workflow. Here the decision record should close only when the authorized party has a documented border outcome and the order state reflects it. A new parcel is not a correction for an unanswered admissibility question. [25] [27]

What to do next

1. Identify the exact item, intended use evidence, U.S. shipper, and named foreign consignee. Keep the item description consistent with the records used for review. [1] [23]

2. Ask a qualified reviewer to document U.S. export classification and the Census EEI filing question for that transaction. Keep the export control and filing answers separate. [2] [3] [4]

3. Check the current USPS country listing and international mail conditions for the identified destination and item. Record the service you intend to use. [5] [6] [7] [8]

4. For Canada, have the importer resolve product category, authorization, licensing, and admissibility with Health Canada where applicable. Name the importer and activity in the response. [9] [10] [11] [12]

5. Have the Canadian importer and broker or courier reconcile CBSA origin, tariff, invoice, and release records. Confirm who owns the customs account and accounting declaration. [14] [15] [28] [29]

6. Complete the postal declaration and any required invoice with the actual item description, quantity, value, and parties. Compare both documents with the product record. [22] [23]

7. Hold tender until missing authorizations are resolved. If a border notice arrives, preserve it and route it to the authorized importer or counsel. [13] [25] [27]

When should you book a peptide business fit call?

Book a fit call when you need to assign owners for product identity, export review, importer documentation, customs data, and escalation before a cross border tender. Bring the item record, intended destination, proposed importer, and open questions. The call can organize the work; it cannot grant legal clearance or shipment approval. [2] [10] [13]

Frequently Asked Questions

Can you ship peptides to Canada?

Only if the specific item meets U.S. export rules and Canadian import rules, since USPS says drugs and medicines must comply with Canadian law and Health Canada says importers must ensure products imported for sale comply with the Act and its Regulations at the time of import. [6][10]

Is it legal to ship peptides in the mail?

Mail acceptance depends on the destination country, because USPS tells mailers to refer to its Individual Country Listings for additional country conditions, and for Canada says drugs and medicines must comply with Canadian law. [5][6]

Does USPS ship peptides?

USPS sets conditions by destination country: its Canada listing says drugs and medicines must comply with Canadian law, its Australia listing says drugs, medicines and therapeutic substances require an import permit from the Australian Department of Health, Office of Drug Control, and its New Zealand listing includes medicines. [6][7][8]

Can you ship peptides to Australia?

The TGA says peptide products regulated as therapeutic goods must be included in the ARTG before they can be imported, manufactured, supplied, exported or advertised, subject to limited exceptions such as a specific approval, authority or exemption. [16][17]

Can you ship peptides to New Zealand?

New Zealand Customs says importing medicines for commercial purposes requires holding a Ministry of Health licence under the Medicines Act 1981 or meeting another condition it lists, and the USPS New Zealand listing includes medicines. [8][21]

Do I need an importer licence to send peptides to Canada?

Health Canada says an importer must have an Establishment Licence for the activity of import for the category of API, and human drugs must have a Drug Identification Number before being marketed in Canada. [11][12]

What happens if Canada stops my peptide shipment?

Health Canada says CBSA officers may detain a health product they suspect does not comply, products found non compliant during inspection will be refused entry or seized, and Health Canada will notify you and the CBSA in writing of the outcome. [25][26][27]

What should the customs declaration say when I ship peptides abroad?

USPS says the declaration needs a detailed description of contents including quantity, net weight and value for each item, and that a false, misleading or incomplete declaration can result in seizure or return of the item and criminal or civil penalties. 22][24] The [China sourcing guide discusses the separate sourcing question for shipments that begin in China.

Sources

These official rules and guidance pages support the cited statements; access dates identify the pages reviewed for this draft.

1. Electronic Code of Federal Regulations, 21 CFR 201.128, accessed 2026-10-05.

2. U.S. Bureau of Industry and Security, Classify your item, accessed 2026-10-05.

3. U.S. Bureau of Industry and Security, Classify your item, accessed 2026-10-05.

4. U.S. Census Bureau, Automated Export System, accessed 2026-10-05.

5. United States Postal Service, Publication 52 international conditions, accessed 2026-10-05.

6. United States Postal Service, Canada individual country listing, accessed 2026-10-05.

7. United States Postal Service, Australia individual country listing, accessed 2026-10-05.

8. United States Postal Service, New Zealand individual country listing, accessed 2026-10-05.

9. Health Canada, Personal use importation of health products guidance, https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/importation-exportation/personal-use-health-products-guidance/document.html, accessed 2026-10-05.

10. Health Canada, Importing and exporting health products for commercial use, https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/importation-exportation/commercial-use-health-products-guidance/document.html, accessed 2026-10-05.

11. Health Canada, Importing and exporting health products for commercial use, https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/importation-exportation/commercial-use-health-products-guidance/document.html, accessed 2026-10-05.

12. Health Canada, Importing and exporting health products for commercial use, https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/importation-exportation/commercial-use-health-products-guidance/document.html, accessed 2026-10-05.

13. Health Canada, Importing and exporting health products for commercial use, https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/importation-exportation/commercial-use-health-products-guidance/document.html, accessed 2026-10-05.

14. Canada Border Services Agency, Importing commercial goods: determine origin, accessed 2026-10-05.

15. Canada Border Services Agency, Importing commercial goods: set up the importing business, accessed 2026-10-05.

16. Therapeutic Goods Administration, How we regulate therapeutic peptide products, https://www.tga.gov.au/products/medicines/monitoring-and-compliance/how-we-regulate-therapeutic-peptide-products, accessed 2026-10-05.

17. Therapeutic Goods Administration, How we regulate therapeutic peptide products, https://www.tga.gov.au/products/medicines/monitoring-and-compliance/how-we-regulate-therapeutic-peptide-products, accessed 2026-10-05.

18. Therapeutic Goods Administration, How we regulate therapeutic peptide products, https://www.tga.gov.au/products/medicines/monitoring-and-compliance/how-we-regulate-therapeutic-peptide-products, accessed 2026-10-05.

19. Therapeutic Goods Administration, How we regulate therapeutic peptide products, https://www.tga.gov.au/products/medicines/monitoring-and-compliance/how-we-regulate-therapeutic-peptide-products, accessed 2026-10-05.

20. Medsafe, Categorisation of products, accessed 2026-10-05.

21. New Zealand Customs Service, Prohibitions and restrictions, accessed 2026-10-05.

22. United States Postal Service, International Mail Manual customs forms, accessed 2026-10-05.

23. United States Postal Service, International Mail Manual customs forms, accessed 2026-10-05.

24. United States Postal Service, International Mail Manual customs forms, accessed 2026-10-05.

25. Health Canada, Importing and exporting health products for commercial use, https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/importation-exportation/commercial-use-health-products-guidance/document.html, accessed 2026-10-05.

26. Health Canada, Importing and exporting health products for commercial use, https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/importation-exportation/commercial-use-health-products-guidance/document.html, accessed 2026-10-05.

27. Health Canada, Importing and exporting health products for commercial use, https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/importation-exportation/commercial-use-health-products-guidance/document.html, accessed 2026-10-05.

28. Canada Border Services Agency, Importing commercial goods: tariff classification, https://www.cbsa-asfc.gc.ca/import/guide-3-eng.html, accessed 2026-10-05.

29. Canada Border Services Agency, Importing commercial goods: release, https://www.cbsa-asfc.gc.ca/import/guide-6-eng.html, accessed 2026-10-05.

Educational and legal disclaimer

This article provides educational information about shipment review and documentation. It is not legal, regulatory, tax, banking, medical, product, import, export, platform, or payment advice. Rules and agency decisions depend on the identified item, parties, route, and current authority. Obtain a transaction specific determination from the relevant authority and qualified advisers before acting. No personal product suitability is assessed here.